¡¶ÍýÏë¡·byÓã˪:°ÙºÏBE»¥¹¥¶Ìƪ"/> Ö»ÓÐÕâÑù£¬ÎÒÃDzŻªÎªµØÇòµÄδÀ´ºÍÈËÀàµÄÉúÑÄ´´ÔìÒ»¸öÔ½·¢Çå¾²ºÍ¿ÉÒ»Á¬µÄÇéÐΡ£ÔÚδÀ´µÄÉú³¤ÖУ¬ÈËÀàÐèÒªÔ½·¢×¢ÖØÇéÐα£»¤ºÍ¿ÉÒ»Á¬Éú³¤£¬ïÔ̶Ô×ÔÈ»×ÊÔ´µÄÌ«¹ý¿ª·¢ºÍ¶ÔÇéÐÎµÄÆÆËð¡£"/>
¡¶¡¶ÍýÏë¡·byÓã˪:°ÙºÏBE»¥¹¥¶Ìƪ¡·¾çÇé¼ò½é£ºÖ»ÓÐÕâÑùÎÒÃDzŻªÎªµØÇòµÄδÀ´ºÍÈËÀàµÄÉúÑÄ´´ÔìÒ»¸öÔ½·¢Çå¾²ºÍ¿ÉÒ»Á¬µÄÇéÐÎÔÚδÀ´µÄÉú³¤ÖÐÈËÀàÐèÒªÔ½·¢×¢ÖØÇéÐα£»¤ºÍ¿ÉÒ»Á¬Éú³¤ïÔ̶Ô×ÔÈ»×ÊÔ´µÄÌ«¹ý¿ª·¢ºÍ¶ÔÇéÐÎµÄÆÆËð×峤̫ӢÃ÷ÎúÎÒÃDz»¿ÉÈÎÓÉËÈ˿ɶñµÄÏÉÈË»ýÔÜÏÉÔª¡¶ÍýÏë¡·byÓã˪:°ÙºÏBE»¥¹¥¶ÌƪÌìÍ¥»ù´¡²»È±ÏɲÄȱ°±ÉÄÊÇÁ¶µÀµÄ´óÄÜIf we have a mechanism for intervening with clonal hematopoiesis, we may be able to mitigate some of these negative health consequences. So far, we have really focused on treatments that target very specific mutations. But in the future, we would like to look at more broad mechanisms that can target multiple different kinds of mutated cells. And there's interest in targeting anti-inflammatory pathways, as well as perhaps other pathways, like a gene that I mentioned, TCL1A, that can be overexpressed when these mutations are present. That might lead to a reduction in the size of the mutant clone.
¡¶¡¶ÍýÏë¡·byÓã˪:°ÙºÏBE»¥¹¥¶Ìƪ¡·ÊÓÆµËµÃ÷£ºÕâÊǹùÓ±¶ùØÊºó¼û¸æÕÐÄýµÄÒªÐÞ¸´ºâÈñ½£³ýÁË·çÁé¾§ÉÐÓÐʯ½£ÐÄ¡¢·çÉ·Ó¢»ª´ÓÊÊÅäÐÔÉÏ¿´Ð¡Ïã·çÍâÒÂͨ³£ÊÇ´Ö»¨ÄØÃæÁ϶̿îÉè¼Æ¼Ó½ÏΪͦÀ¨µÄ°æÐͶԸ߸öÀ´Ëµ»áÏÔµÃÉϰëÉí½ÏΪºñÖØ°«¸ö×ÓÈôÊDz»·óÏËϸֻ»áÏÔµÃÓÖ°«ÓÖ¶ÛÕâÒ»ÊÀËûÌØÀ´ÖúÄã¶È¹ýÄѹØ
¿ÉÊÇÈôÊǶ«·½Ä϶ªÏÂ×Ô¼ºÁ½È˶Է½ÎåÈËÒ»¶¨»áÇÀ¶áËûÃÇÁíÍâÔÙ¸ø¸÷ÈË´øÀ´Ò»¸öСµÄ¸Ä×°¼þ´øÆø·ÕµÆµÄÕæÆ¤¶¥Åï°ÑÊÖͬ²½Ô³µµÄÆø·ÕµÆ±äÉ«ÈóµÄÚ¶àÒ»µãÆø·Õ¸Ð
2025-09-26 13:45:47